332 related articles for article (PubMed ID: 30476528)
21. Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis.
Yu W; He X; Yang Z; Yang X; Xiao W; Liu R; Xie R; Qin L; Gao H
Biomaterials; 2019 Oct; 217():119309. PubMed ID: 31271855
[TBL] [Abstract][Full Text] [Related]
22. A size-shrinkable matrix metallopeptidase-2-sensitive delivery nanosystem improves the penetration of human programmed death-ligand 1 siRNA into lung-tumor spheroids.
Wen J; Qiu N; Zhu Z; Bai P; Hu M; Qi W; Liu Y; Wei A; Chen L
Drug Deliv; 2021 Dec; 28(1):1055-1066. PubMed ID: 34078185
[TBL] [Abstract][Full Text] [Related]
23. Enhancing the antitumor immunosurveillance of PD-L1-targeted gene therapy for metastatic melanoma using cationized Panax Notoginseng polysaccharide.
Ma M; Liu X; Ma C; Guo R; Zhang X; Zhang Z; Ren X
Int J Biol Macromol; 2023 Jan; 226():1309-1318. PubMed ID: 36442564
[TBL] [Abstract][Full Text] [Related]
24. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
[TBL] [Abstract][Full Text] [Related]
25. RNAi mediated silencing of STAT3/PD-L1 in tumor-associated immune cells induces robust anti-tumor effects in immunotherapy resistant tumors.
Ganesh S; Kim MJ; Lee J; Feng X; Ule K; Mahan A; Krishnan HS; Wang Z; Anzahaee MY; Singhal G; Korboukh I; Lockridge JA; Sanftner L; Rijnbrand R; Abrams M; Brown BD
Mol Ther; 2024 Jun; 32(6):1895-1916. PubMed ID: 38549376
[TBL] [Abstract][Full Text] [Related]
26. PD-L1 knockdown via hybrid micelle promotes paclitaxel induced Cancer-Immunity Cycle for melanoma treatment.
Tang X; Rao J; Yin S; Wei J; Xia C; Li M; Mei L; Zhang Z; He Q
Eur J Pharm Sci; 2019 Jan; 127():161-174. PubMed ID: 30366077
[TBL] [Abstract][Full Text] [Related]
27. Integrin α
Chen H; Zhao L; Fu K; Lin Q; Wen X; Jacobson O; Sun L; Wu H; Zhang X; Guo Z; Lin Q; Chen X
Theranostics; 2019; 9(25):7948-7960. PubMed ID: 31695808
[TBL] [Abstract][Full Text] [Related]
28. Landscape of PD-1/PD-L1 Regulation and Targeted Immunotherapy.
Ni JM; Ni AP
Chin Med Sci J; 2018 Sep; 33(3):174-182. PubMed ID: 30266108
[TBL] [Abstract][Full Text] [Related]
29. Synergistically enhanced cancer immunotherapy by combining protamine-based nanovaccine with PD-L1 gene silence nanoparticle.
Jiang M; Chen W; Sun Y; Zeng J; Ma L; Gong J; Guan X; Lu K; Zhang W
Int J Biol Macromol; 2023 Jul; 242(Pt 4):125223. PubMed ID: 37276908
[TBL] [Abstract][Full Text] [Related]
30. Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.
Traini G; Ruiz-de-Angulo A; Blanco-Canosa JB; Zamacola Bascarán K; Molinaro A; Silipo A; Escors D; Mareque-Rivas JC
Small; 2019 Jan; 15(4):e1803993. PubMed ID: 30569516
[TBL] [Abstract][Full Text] [Related]
31. Novel Dual-Mode NIR-II/MRI Nanoprobe Targeting PD-L1 Accurately Evaluates the Efficacy of Immunotherapy for Triple-Negative Breast Cancer.
Liu WL; Zhang YQ; Luo XJ; Zhu YY; Song L; Ming ZH; Zhang LX; Li MJ; Lv RC; Zhang GJ; Chen M
Int J Nanomedicine; 2023; 18():5141-5157. PubMed ID: 37705867
[TBL] [Abstract][Full Text] [Related]
32. Soluble monomeric human programmed cell death-ligand 1 inhibits the functions of activated T cells.
Liang Z; Chen W; Guo Y; Ren Y; Tian Y; Cai W; Bao Y; Liu Q; Ding P; Li Y
Front Immunol; 2023; 14():1133883. PubMed ID: 37266424
[TBL] [Abstract][Full Text] [Related]
33. DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy.
Zhang R; Wan Y; Lv H; Li F; Lee CS
J Mater Chem B; 2021 Sep; 9(36):7544-7556. PubMed ID: 34551052
[TBL] [Abstract][Full Text] [Related]
34. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
[No Abstract] [Full Text] [Related]
35. Co-inhibition of the TGF-β pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy.
Wang Y; Gao Z; Du X; Chen S; Zhang W; Wang J; Li H; He X; Cao J; Wang J
Biomater Sci; 2020 Sep; 8(18):5121-5132. PubMed ID: 32820750
[TBL] [Abstract][Full Text] [Related]
36. Synergistic and low adverse effect cancer immunotherapy by immunogenic chemotherapy and locally expressed PD-L1 trap.
Song W; Shen L; Wang Y; Liu Q; Goodwin TJ; Li J; Dorosheva O; Liu T; Liu R; Huang L
Nat Commun; 2018 Jun; 9(1):2237. PubMed ID: 29884866
[TBL] [Abstract][Full Text] [Related]
37. Personalized Tumor RNA Loaded Lipid-Nanoparticles Prime the Systemic and Intratumoral Milieu for Response to Cancer Immunotherapy.
Sayour EJ; Grippin A; De Leon G; Stover B; Rahman M; Karachi A; Wummer B; Moore G; Castillo-Caro P; Fredenburg K; Sarkisian MR; Huang J; Deleyrolle LP; Sahay B; Carrera-Justiz S; Mendez-Gomez HR; Mitchell DA
Nano Lett; 2018 Oct; 18(10):6195-6206. PubMed ID: 30259750
[TBL] [Abstract][Full Text] [Related]
38. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.
Hara T; Miyake H; Hinata N; Fujisawa M
Anticancer Res; 2019 Sep; 39(9):4737-4742. PubMed ID: 31519573
[TBL] [Abstract][Full Text] [Related]
40. Identification of a novel PD-L1 positive solid tumor transplantable in HLA-A*0201/DRB1*0101 transgenic mice.
Rangan L; Galaine J; Boidot R; Hamieh M; Dosset M; Francoual J; Beziaud L; Pallandre JR; Lauret Marie Joseph E; Asgarova A; Borg C; Al Saati T; Godet Y; Latouche JB; Valmary-Degano S; Adotévi O
Oncotarget; 2017 Jul; 8(30):48959-48971. PubMed ID: 28430664
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
